Innovation in Connectivity Roundtable pt. 2

More modern, our new brand identity truly embodies who we are, how we partner with our customers and ultimately the value we bring to millions of patients across the world through our drug delivery device solutions.

The Innovation in Connectivity Roundtable originally aired as part of Pharmapack Europe 2021 Part 1 of this session includes three presentations: Patient Journey Driven Considerations for Integrating Digital Health for Combination Products The importance of utilizing applied ethnography and other primary research methods to understand the patient journey as the foundation for integrating digital health into a device/combination product development initiative. Considering patient needs in the context of a larger ecosystem including providers, payers, and regulators to develop a robust plan with respect to connectivity and digital health. Examples of how this understanding is applied across the combination product development journey through organic development, utilization of platform devices, or as a lifecycle management enchantments while optimizing the user experience resulting in safe, effective, and differentiated combination products. Mark Tunkel, Global Category Director for Insight Innovation, Nemera Electronic Product Information: A Case Study on Medicine Labelling for the Visually Impaired The Electronic Product Information Initiative for Medicines (ePI) aim to ease the accessibility of product information to everyone, including visually impaired patients. The GS1 Digital Link aim to provide a single barcode for identification, brand protection, and access to product information for patients. Our lecture will illustrate how the existing Datamatrix on packaging could be leveraged, today, by everyone, including visually impaired users, to access a tailored and relevant information. Laurent Tonnelier, CEO, mobiLead - xTag Lise Wagner, Accessibility Specialist and User Expert, OKEENEA Traceability of Medicines: from Finished Product to Unit Dose Delivery Challenges for B2B Supply Chain stakeholders Regulations: a global overview What about B2C Nathalie Wardé, CEO & Founder, D4P pharma Join the above speakers and moderator Lionel Jeannin, Group Head Oral Packaging & Delivery Systems, Novartis Pharma AG for the live panel discussion that followed in the Innovation in Connectivity Roundtable pt. 2

Awards showcased a wide range of industry-changing innovations in packaging and drug delivery, with sustainability emerging as a key metric across all categories

During the live Innovation in Connectivity Roundtable at the Pharmapack 2021 online conference, experts discussed how the latest innovations in digital technology are shaping industry ambitions to put the patient journey at the heart of its drug device and delivery solutions by simplifying product information via increased connectivity.

This webinar will address: Key market trends in digital health and how they have accelerated in the past years Nemera’s vision of digital health and the implications on the whole drug/device development ecosystem – how connectivity is creating incredible opportunities for the industry but also raises some challenges: link to conferences in the track How does Nemera play in this landscape: presentation of the company, our capabilities and some examples of our connected devices. Webinar originally aired as part of Pharmapack Europe 2021

While patient centricity is the foundation for developing a robust device selection plan and completion of a successful combination product development initiative, developers need to remember there is a larger ecosystem that must be considered to ensure success.

As a world-leading drug delivery device solutions provider, our purpose of putting patients first enables us to design and manufacture devices that maximize treatment efficacy. We are a holistic partner and help our customers succeed in the sprint to market of their combination products. From early device strategy to state-of-the-art manufacturing, we’re committed to the highest quality standards. Agile and open-minded, we work with our customers as colleagues. Together, we go the extra mile to fulfill our mission.
For more information, visit www.nemera.net

Nemera is excited to announce that its multidose eye dropper Novelia® has been approved by ANVISA for the preservative-free formulations CLILON [1] (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat moderately severe pain and inflammation, usually after surgery.

Our CEO, Marc Hämel shares the lessons we learned from last year, extends his wishes, gratitude to the Nemera family and walks us through the top company goals that will shape and drive our story in 2021!

In this report, Alira Health in partnership with MassMEDIC analyzes the rapidly evolving DDD landscape and how industry leaders like Nemera strive to enhance the end-to-end services offering by integrating the pharmaceutical value chain.

Our VP strategy and marketing and our director of business development, Insight Innovation Center are presenting Nemera and its portfolio. They are giving more details about Insight Innovation Center.

Our ophthalmic experts discuss the challenges glaucoma and dry eye patients face with eye drop administration and present the Novelia® system featuring patented PureFlow® technology, which controls the medication flow.

Nemera, Juan Sarmien, Sales Director for North America at Nemera, speaks with CPHI TV at CPHI Worldwide in Madrid.

Nemera announced that they have entered into an agreement to acquire Milfra. Milfra, based in Jaguariuna, state of São Paulo, Brazil, specializes in the development and production of both vaginal and rectal applicators, as well as oral dosers for the pharmaceutical industry. A family-owned company f...

This partnership expands offer of diabetes medicines in the country; Nemera’s Advapen launch happens under the trade name Lifepen® for the administration of Glargilin insulin for the treatment of diabetes A pioneer in biotechnological medicines in Brazil, BIOMM is launching Nemera’s Advapen under the trade name Lifepen® for the administration of Glargilin insulin for the treatment of diabetes.

Our proven experience in the complementary activities surrounding drug delivery device and combination product development, alongside our strong know-how in our industry ecosystem, puts us in an optimal place to support our customers as partners through every step in their journey. By keeping the patient top of mind, we create success on all fronts. We aim to improve patients’ outcomes and build customer success. In order to do that, we have three key pillars that form the base of our organizational identity: • Patients first. Always. • Partnering in drug delivery devices. Holistically. • Going the extra mile. Together. Our new logo and a new brand style convey this message to customers, applicants, shareholders, and other stakeholders, with a fresh, friendly, and moving-forward look and feel.

Nemera today announced that they have entered into an agreement to acquire Copernicus. Copernicus, based in Szczecin Poland, specializes in the development and manufacturing of injection devices. Their range of reusable and disposable pen injectors are tailored for the treatment of several chronic pathologies.

As one of the world’s leading providers of design, development and manufacturing of drug delivery devices, we announced the conclusion of a collaboration agreement with Noble, global provider of medical device training solutions and patient onboarding strategies for the world’s top pharmaceutical and biotechnology brands. On this occasion, the latest issue of ‘The Pharmaceutical post’ publish an article about the collaboration between Nemera and Noble.

In the pharmaceutical industry, we can see the development of generics is significantly growing. This trend is mainly driven by countries to give patients easier access to drugs and to define regulations accordingly.

RetroNose is a completely new drug delivery concept to dispense drug formulation to the nasal cavity. The principle of this concept is to deliver a spray through the oral cavity to deposit the drug in the nasal cavity from rear to front. To avoid aerosol penetration in the lung and to ensure deposition efficacy, the aerosol drug is automatically delivered during the nasal expiratory phase.